脓毒症患者血浆乙酰肉碱升高与多器官功能障碍及死亡率相关:一项多中心队列研究
该研究为前瞻性多中心队列研究,采用推导与验证队列设计,在台湾两个医学中心和三个区域医院的ICU纳入脓毒症合并急性器官功能障碍患者,推导队列n=90(2010年10月至2012年3月),验证队列n=120(2013年1月至2014年11月)。入院后立即采集血浆,用超高效液相色谱-质谱法测定肉碱和酰基肉碱水平。推导队列中短链和中链酰基肉碱升高与肝胆功能障碍、肾功能障碍、血小板减少和高乳酸血症显著相关,但乙酰肉碱是唯一与多种血浆细胞因子浓度显著相关、并与血培养阳性和28天死亡风险相关的酰基肉碱;验证队列证实了血浆乙酰肉碱与多器官功能障碍严重程度、血培养阳性和28天死亡率的关联。高血浆乙酰肉碱(≥6,000 ng/mL)患者28天死亡率显著高于低于6,000 ng/mL者(52.6% vs 13.9%;HR 5.293;95%CI 2.340-11.975;p<0.001)。
要点
- 脓毒症合并急性器官功能障碍患者入院时血浆乙酰肉碱≥6,000 ng/mL者28天死亡率为52.6%,低于6,000 ng/mL者为13.9%(HR 5.293;95%CI 2.340-11.975;p<0.001)。
- 验证队列证实血浆乙酰肉碱与多器官功能障碍严重程度、血培养阳性和28天死亡率相关。
- 推导队列中短链和中链酰基肉碱升高与肝胆功能障碍、肾功能障碍、血小板减少和高乳酸血症显著相关。
- 乙酰肉碱是唯一与多种血浆细胞因子浓度显著相关、并与血培养阳性和28天死亡风险相关的酰基肉碱。
- 血浆乙酰肉碱可作为脓毒症预后生物标志物,反映器官功能障碍严重程度、炎症和感染。
适用人群与场景
- 纳入脓毒症合并急性器官功能障碍的ICU患者,来自台湾两个医学中心和三个区域医院。
- 推导队列n=90,招募时间2010年10月至2012年3月;验证队列n=120,招募时间2013年1月至2014年11月。
诊断标准与关键阈值
- 高血浆乙酰肉碱定义为≥6,000 ng/mL,低于6,000 ng/mL为对照。
处置流程与药物剂量
- 入院后立即采集血浆样本,用超高效液相色谱-质谱法测定肉碱和酰基肉碱水平。
研究设计与关键结果
- 前瞻性多中心队列研究,采用推导与验证队列设计,推导队列n=90、验证队列n=120,纳入脓毒症合并急性器官功能障碍患者。
- 推导队列中短链和中链酰基肉碱升高与肝胆功能障碍、肾功能障碍、血小板减少和高乳酸血症显著相关。
- 乙酰肉碱是唯一与多种血浆细胞因子浓度显著相关、并与血培养阳性和28天死亡风险相关的酰基肉碱。
- 验证队列证实血浆乙酰肉碱与多器官功能障碍严重程度、血培养阳性和28天死亡率相关。
- 高血浆乙酰肉碱(≥6,000 ng/mL)患者28天死亡率52.6%,低于6,000 ng/mL者13.9%(HR 5.293;95%CI 2.340-11.975;p<0.001)。
证据类型、等级与局限
- 证据类型:前瞻性多中心队列研究,采用推导与验证队列设计。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为血浆乙酰肉碱可反映脓毒症器官功能障碍严重程度、炎症和感染,可作为死亡率预测的预后生物标志物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Recent metabolomic studies of sepsis showed that increased circulatory acylcarnitines were associated with worse survival. However, it is unknown whether plasma carnitine and acylcarnitines can reflect the severity of sepsis, and the role of specific acylcarnitines in prognostic assessment need further confirmation. This study aimed to clarify these questions.
DESIGN: Prospective multicenter cohort studies with derivation and validation cohort design.
SETTING: ICUs at two medical centers and three regional hospitals in Taiwan.
PATIENTS: Patients with sepsis and acute organ dysfunction were enrolled. Recruitment of the derivation (n = 90) and validation cohorts (n = 120) occurred from October 2010 through March 2012 and January 2013 through November 2014, respectively.
INTERVENTIONS: Plasma samples were collected immediately after admission, and the levels of carnitine and acylcarnitines were measured by ultra-high performance liquid chromatography-mass spectrometry.
MEASUREMENTS AND MAIN RESULTS: In the derivation cohort, increased plasma levels of short- and medium-chain acylcarnitines were significantly associated with hepatobiliary dysfunction, renal dysfunction, thrombocytopenia, and hyperlactatemia. However, acetylcarnitine is the only acylcarnitine significantly correlating with various plasma cytokine concentrations and also associated with blood culture positivity and 28-day mortality risk. The association between plasma acetylcarnitine and multiple organ dysfunction severity, blood culture positivity, and 28-day mortality, was confirmed in the validation cohort. Patients with high plasma acetylcarnitine (≥ 6,000 ng/mL) had significantly increased 28-day mortality compared with those with plasma acetylcarnitine less than 6,000 ng/mL (52.6% vs 13.9%; hazard ratio, 5.293; 95% CI, 2.340-11.975; p < 0.001 by Cox proportional hazard model).
CONCLUSIONS: We confirm that plasma acetylcarnitine can reflect the severity of organ dysfunction, inflammation, and infection in sepsis and can serve as a prognostic biomarker for mortality prediction.
参考来源
- Chung KP, Chen GY, Chuang TY, et al. Increased Plasma Acetylcarnitine in Sepsis Is Associated With Multiple Organ Dysfunction and Mortality: A Multicenter Cohort Study. Crit Care Med. 2019. PMID: 30379669. doi:10.1097/CCM.0000000000003517
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。